Get the Stockscreener App
2.19
4.78%
0.10
After Hours:
2.25
0.06
+2.74%
Immix Biopharma Inc stock is traded at $2.19, with a volume of 567.57K.
It is up +4.78% in the last 24 hours and up +0.00% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$2.09
Open:
$2.22
24h Volume:
567.57K
Relative Volume:
2.79
Market Cap:
$63.15M
Revenue:
-
Net Income/Loss:
$-14.14M
P/E Ratio:
-2.3804
EPS:
-0.92
Net Cash Flow:
$-12.64M
1W Performance:
+4.29%
1M Performance:
+0.00%
6M Performance:
+12.31%
1Y Performance:
+23.73%
1-Day Range:
$2.09
$2.2533
1-Week Range:
$1.94
$2.2533
52-Week Range:
$1.26
$3.12
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
2.19 | 68.27M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Immix Biopharma Inc Stock (IMMX) Latest News
Does Immix Biopharma Inc have consistent dividend growthWeekly Profit Analysis & Smart Swing Trading Alerts - khodrobank.com
Using economic indicators to assess Immix Biopharma Inc. potentialMarket Performance Recap & Risk Controlled Swing Trade Alerts - newser.com
What does recent volatility data suggest for Immix Biopharma Inc.2025 Market Overview & Daily Price Action Insights - newser.com
Daily Brief Health Care: Vivani Medical, Medcaptain Medical Technology, Dr Lal PathLabs Ltd, Immix Biopharma Inc, MDxHealth SA, Oncology Institute and more - Smartkarma
Will a bounce in Immix Biopharma Inc. offer an exit2025 AllTime Highs & Weekly High Return Opportunities - newser.com
Measuring Immix Biopharma Inc.’s beta against major indices2025 Short Interest & Growth Oriented Trading Recommendations - newser.com
Heatmap analysis for Immix Biopharma Inc. and competitorsJuly 2025 Institutional & Long-Term Investment Growth Plans - newser.com
Immix Biopharma — NEXICART-2 enrolment progressing well - Smartkarma
Market Rankings: Is Immix Biopharma Inc benefiting from innovation trends2025 Valuation Update & Technical Confirmation Trade Alerts - khodrobank.com
Immix Biopharma surpasses 50% enrollment milestone in AL amyloidosis trial - Investing.com India
Immix Biopharma says that 50% enrollment has already been surpassed in NEXICART-2 - MarketScreener
Regression analysis insights on Immix Biopharma Inc. performanceBond Market & Comprehensive Market Scan Insights - newser.com
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2 - Investing News Network
Immix Biopharma Surpasses 50% Enrollment Milestone in NEXICART-2 Clinical Trial for AL Amyloidosis, Paving the Way for FDA BLA Submission - Quiver Quantitative
Immix Biopharma Announces 50% Enrollment Milestone - GlobeNewswire
First Potential FDA-Approved CAR-T Therapy: ImmixBio's AL Amyloidosis Trial Hits Major Milestone - Stock Titan
Has Immix Biopharma Inc. found a price floorSwing Trade & Proven Capital Preservation Tips - newser.com
Wall Street Recap: How liquid is Immix Biopharma Inc. stockMarket Growth Summary & Technical Buy Zone Confirmation - khodrobank.com
MACD Signal: Can Amalgamated Financial Corp stock double in the next year2025 Winners & Losers & Short-Term Swing Trade Alerts - khodrobank.com
Hunton Represents Goose Capital in Immix Biopharma Investment - Hunton Andrews Kurth LLP
Resistance Check: Does Immix Biopharma Inc have consistent dividend growth2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - khodrobank.com
Insider Buying: Ilya Rachman Acquires Additional Shares of Immix Biopharma Inc (IMMX) - GuruFocus
Immix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Immix Biopharma Inc. stock momentum explainedMarket Growth Report & Technical Analysis for Trade Confirmation - newser.com
Analyzing Immix Biopharma Inc. with multi timeframe chartsSell Signal & AI Powered Market Entry Strategies - newser.com
Stock Recap: Is INDV gaining market shareMarket Sentiment Summary & AI Driven Stock Price Forecasts - خودرو بانک
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update - MarketBeat
Aug Spikes: Can Immix Biopharma Inc. stock outperform in a bear marketShort Setup & Smart Investment Allocation Insights - khodrobank.com
Buy Signal: Is Immix Biopharma Inc in a bullish channelJuly 2025 Decliners & Target Return Focused Stock Picks - khodrobank.com
Market Recap: Can Immix Biopharma Inc. grow without external fundingPrice Action & Daily Chart Pattern Signals - خودرو بانک
Does Immix Biopharma Inc. qualify in momentum factor screeningJuly 2025 Gainers & Free Reliable Trade Execution Plans - newser.com
Retail Surge: Can XYZG expand into new marketsJuly 2025 PostEarnings & Stepwise Trade Signal Guides - خودرو بانک
Market Catalysts: Is Immix Biopharma Inc benefiting from innovation trendsJuly 2025 Spike Watch & Precise Buy Zone Identification - khodrobank.com
Earnings Recap: How cyclical is Immix Biopharma Inc.’s revenue stream2025 EndofYear Setup & High Accuracy Investment Signals - خودرو بانک
Will Immix Biopharma Inc. rebound enough to break even2025 Momentum Check & Risk Controlled Stock Pick Alerts - newser.com
S P Trends: Is Immix Biopharma Inc. stock a good dividend stockWeekly Risk Report & Proven Capital Preservation Methods - khodrobank.com
HC Wainwright Forecasts Strong Price Appreciation for Immix Biopharma (NASDAQ:IMMX) Stock - Defense World
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):